BRAF and melanoma: Notably, after treatment with nivolumab and ipilimumab, melanoma patients with BRAF mutant had significantly higher OS at five years than those without BRAF mutation (60% vs. 48%), suggesting that the immune microenvironment of BRAF-mutant melanoma may be distinct from that of wild type melanoma.